Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.58 |
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.57 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.57 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.52 |
| ▸ | NPY2R | P49146 | 4/20 | 0.50 |
| ▸ | NPY4R | P50391 | 4/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.50 |
| ▸ | NPY1R | P25929 | 3/20 | 0.50 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.50 |
| ▸ | CALCR | P30988 | 1/20 | 0.50 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29864813 | 1.00 | OPRM1 (0.58) | OPRM1OPRD1NMUR2NMUR1EPHA2 | |
| SCHEMBL29864890 | 1.00 | OPRM1 (0.58) | OPRM1OPRD1NMUR2NMUR1EPHA2 | |
| SCHEMBL29865208 | 1.00 | OPRM1 (0.58) | OPRM1OPRD1NMUR2NMUR1EPHA2 | |
| SCHEMBL29864827 | 1.00 | OPRM1 (0.58) | OPRM1OPRD1NMUR2NMUR1EPHA2 | |
| SCHEMBL29865201 | 0.96 | OPRM1 (0.56) | OPRM1OPRD1NMUR2NMUR1EPHA2 | |
| SCHEMBL29865057 | 0.96 | OPRM1 (0.56) | OPRM1OPRD1NMUR2NMUR1EPHA2 | |
| SCHEMBL29865041 | 0.95 | OPRM1 (0.62) | OPRM1OPRD1NMUR2NMUR1EPHA2 | |
| SCHEMBL29864847 | 0.95 | OPRM1 (0.62) | OPRM1OPRD1NMUR2NMUR1EPHA2 | |
| SCHEMBL29865083 | 0.95 | OPRM1 (0.62) | OPRM1OPRD1NMUR2NMUR1EPHA2 | |
| SCHEMBL29864816 | 0.94 | OPRM1 (0.59) | OPRM1OPRD1NMUR2NMUR1EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220378950-A1 | COMPOUNDS HAVING RD TARGETING MOTIFS AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY | 2022-12-01 | — | — | US | disclosed |
| US-11413359-B2 | Compounds having RD targeting motifs and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2022-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11413359-B2 | Compounds having RD targeting motifs and methods of use thereof | DDR1, ILK, CD47 | OPRM1 2492/4885OPRD1 2667/4885NMUR2 815/4885 |
| US-20220378950-A1 | COMPOUNDS HAVING RD TARGETING MOTIFS AND METHODS OF USE THEREOF | DDR1, CD47, ILK | OPRM1 2416/4885OPRD1 2622/4885NMUR2 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.